Chemistry: molecular biology and microbiology – Measuring or testing process involving enzymes or... – Involving antigen-antibody binding – specific binding protein...
Patent
1993-08-19
1996-06-25
Scheiner, Toni R.
Chemistry: molecular biology and microbiology
Measuring or testing process involving enzymes or...
Involving antigen-antibody binding, specific binding protein...
435 792, 435 793, 435 794, 435 795, 436506, 436811, G01N 3353, G01N 33564
Patent
active
055298982
ABSTRACT:
A method of screening a subject for a central nervous system disorder caused by autoimmune disease (e.g., an inflammatory seizure disorder) comprises a sample from the subject and then detecting the presence or absence of anti-glutamate receptor autoantibodies (e.g., anti-GluR3 glutamate receptor autoantibodies) in the biological sample. The presence of such autoantibodies indicates the subject is afflicted with a central nervous system disorder caused by autoimmune disease. Methods of treating such disease by reducing the number of autoantibodies available to bind to glutamate receptors in the subject are also disclosed.
REFERENCES:
patent: 4747952 (1988-05-01), Nakano et al.
patent: 4925787 (1990-05-01), Tanihara et al.
H. L. Weiner et al., Double-Blind Pilot Trial of Oral Tolerization with Myelin Antigens in Multiple Sclerosis Science 259, 1321-1324 (1993).
Current Practice in Therapeutic Plasmapheresis Proceedings of two symposia held at the 17th International Congress of Internal Medicine, Kyoto, Oct. 11, and 12, pp. 158-177 (1984).
Plasma Exchange Therapy in Neurological Disorders: A Clinician's Overview, Therapeutic Hemapheresis II pp. 27-54 CRC Press, 1985.
Apheresis in the Treatment of Neurological Diseases, Therapeutic Apheresis Chapter 4, pp. 35-58 (1983), American Association of Blood Banks.
W. G. Honer et al., Characterization of a Synaptic Antigen of Interest in Neuropsychiatric Illness Biol. Psychiatry 31, 147-158 (1992).
D. W. Choi, Glutamate Neurotoxicity and Diseases of the Nervous System Neuron 1(8)623-634, 1988.
J. O. McNamara and Inwin Fridovich, Did Radicals Strike Lou Gehrig Nature, pp. 20-22 (1993).
R. Dingledine et al., Excitatory amino acid receptors in epilepsy TIPS 11, pp. 334-338 (1990).
G. P. Gasic and Michael Hollmann, Molecular Neurobiology of Glutamate Receptors Annu. Rev. Physiol. 54, 507-536 (1992).
M. Barinaga; Antibodies Linked to Rare Epilepsy, Science 268, pp. 362-363 (21 Apr. 1995).
R. E. Twyman et al; Glutamate Receptor Antibodies Activate a Subset of Receptors and Reveal on Agonist Binding Site, Neuron 14, pp. 755-762 (Apr. 1995).
Gorman et al., "Humanisation of monoclonal antibodies for therapy" Immunology, vol. 2 pp. 457-466 (1990).
Rogers S. W. et al. "Autoantibodies to Glutamate Receptor GluR3 in Rasmussen's Encephalitis". Science 265:648-651, 1994.
Ettlinger, G. and Lowrie, M. B. "An Immunological Factor in Epilepsy," The Lancet (i) 1386, 1977.
Piatt J. H. et al. "Chronic Focal Encephalitis (Rasamussen Syndrome): Six Cases". Epilepsia 29(3) 268-279, 1988.
Bouma, P. A. D. "Determining the Prognosis of Childhood Epilepsy by Establishing Immune Abnormalities," Clinical Neurology and Neurosurgery 94 (Suppl.): 554-556, 1992.
Heinemann Stephen F.
McNamara, Sr. James O.
Rogers Scott W.
Duffy Patricia A.
Duke University
Scheiner Toni R.
The Salk Institute for Biological Studies
LandOfFree
Methods of detecting disorders of the central nervous system by does not yet have a rating. At this time, there are no reviews or comments for this patent.
If you have personal experience with Methods of detecting disorders of the central nervous system by , we encourage you to share that experience with our LandOfFree.com community. Your opinion is very important and Methods of detecting disorders of the central nervous system by will most certainly appreciate the feedback.
Profile ID: LFUS-PAI-O-2188128